We're expecting our Standard Processing License in Q4 2020!
What does that mean for Everest?
Allow Everest to acquire cannabis for processing into value-added products.
Allow Everest to process Cannabis for existing and newly licenced growers including the hundreds who are obtaining Micro Grow licences after October 17, 2018.
Allow Everest to trade within a global network; we can Import and Export Cannabis.
Allow Everest to sell the imported product to the Medical Market, such as Big Pharma after we process it
Allow Everest to create formulations of CBD/THC to meet the consumer's needs. Ideal for selling to provincially approved distributors, pharmacies with drug licences and doctors with sale licences under the Cannabis Regulations
Allow Everest to produce formulations in a variety of products for our licensed customers in the beverages, food and vaping markets, legalized in February 2019.
Allow Everest to obtain an R&D license for developing valuable Intellectual Property based on novel product formulations
Advantages of a standard processing license
The advantages of the Standard Processing Licence are that it authorizes all the activities of those permitted under the previous Access to Cannabis for Medical Purposes Regulations (ACMPR), with the exception of growing. With the promulgation of regulations following the legalization of cannabis the medical purposes restriction has been removed and the sale of products for adult use is now permitted. This opens up a gigantic market for the company’s cannabis processing with its own product sales and trading in cannabis domestically and internationally with high-profit margins.
The company’s license for processing will also authorize related activities, including possession, transportation, research and development, storage, destruction, and the intra-industry sale of cannabis to other federal licence holders or provincially or territorially-authorized sellers.
The third source of revenue and profits is possible as the Standard Processing License permits the import and export of cannabis for medical purposes, and between cannabis licensees in Canada.
Because the company’s business model is expected to produce revenue and profits in a short time, attractive returns via dividends are planned.